Mucoid alginate-producing mutants of Pseudomonas aeruginosa are major pathogens in debilitating chronic pulmonary infections in patients with cystic fibrosis. The mucoid phenotype results from alginate biosynthesis whose genes are arranged in at least three chromosomal loci. Structural genes are located at the 34-min region and regulatory genes at 9 min. A third cluster at the 70 rain region contains muc mutations which affect transcription of a key structural gene, algD, in response to environmental stimuli. Control of mucoidy includes bacterial signal transduction systems, histone-like elements controlling nucleoid structure and, possibly, factors affecting superhelicity. Thus, the control of mucoidy in P. aeruginosa has become one of the focal systems for analysis of how bacterial pathogens adapt to the host environment.
INTRODUCTION
An important characteristic of pseudomonads is the ability of some species to synthesise alginate, a family of unbranched (1-4)-linked polysaccharides comprised of /3-D-mannuronate and its C5-epimer a-L-guluronate [1] . Alginates have commercial importance as stabilisers and gelling agents and, in medical microbiology, as determinants of bacterial virulence [1, 2] . This paper will focus on the use of genetic and molecular approaches to clarify the regulation of alginate biosynthesis in mucoid variants of P. aeruginosa (MPA) which are major pulmonary pathogens in patients with cystic fibrosis (CF).
MUCOID P. AERUGINOSA
In P. aeruginosa alginate biosynthesis is usually repressed, hence typical isolates are nonmucoid when cultured on agar media; in contrast, alginate-producing variants produce a mucoid phenotype. Although MPA were described as early as 1927 (ref. 3 ; Bacterium pyocyaneum mu-cosum), present interest in the phenotype originates from the 1960s as a result of studies by Doggett and colleagues demonstrating the association of MPA with the CF lung [4] . Although there is general acceptance that MPA result from in vivo conversion following initial colonisation by nonmucoid P. aeruginosa (NMPA) there has been scanty published evidence to support this hypothesis until the report of an epidemiological study which documented the in vivo transition to the mucoid phenotype in two CF patients following water-borne acquisition of the same NMPA strain [5] . The association of MPA with the pathophysiology of CF lung infection is also established including the role of alginate as an adhesin for respiratory epithelia [6] and in the formation of bronchial plugs and bacterial microcolonies which 'frustrate' phagocytosis and antibiotic therapy leading to immune-mediated lung damage [2, 7] . Interestingly, a recent isolation of MPA from an equine pharynx has confirmed the pulmonary predilection of the phenotype and provides an unusual parallel between veterinary and human microbiology [8] .
Muc mutations
Following the in vitro isolation of mucoid variants of P. aeruginosa PAO using a selection technique based on enhanced antibiotic resistance [9] , mutations associated with conjugal transfer of the mucoid phenotype to P. aeruginosa PAO derivatives were identified and designated muc [10] . These early genetic studies revealed a cluster of muc mutations which showed linkage with the chromosomal markers cys-59 and hisI located at the 10 min region. Further progress was frustrated, however, by anomalous linkage data based on the location of cys-59/hisl and other markers in the region. The problem was solved on recalibration of the PAO map in 1987 and relocation of cys-59/hisI to the 70 min region [11] . The revised locus for cys-59/hisI and the availability of additional markers in this relatively 'dark region' of the chromosome revived interest in muc mutations and led to the demonstration of two distinct muc loci on the PAO chromosome; the first contained muc-23 located between hisI and proB in the 69 min region and a second cluster contained the phenotypically distinct mutations muc-2 and muc-22 which were co-transducible with pru-354 and lay between pru-354 and hisl at the 67 min region [12, 13] . Although these genetic studies had been carried out on PAO mucoid strains which were phenotypically similar to MPA from CF patients there was no assurance that such mutants bore any relationship to MPA from CF patients. The possibility that PAO mucoid strains might be genetically distinct from MPA isolated from CF patients was dispelled by the demonstration that a muc locus in the CF isolate P. aeruginosa 492c could be mapped by a R68.45-mediated interstrain cross with PAO 1042 and was located at the 67 min region between put-70 and hisl [12, 13] . In a second approach, the locus responsible for mucoidy in the CF isolate P. aeruginosa 3739 (muc-3739) and four other CF isolates was transferred by means of pM060-mediated conjugation to PAO and shown to map in the same region as muc-2, muc-22 and muc492c [14] . Additional evidence of the similarity in muc mutations in PAO and clinical isolates came from construction of an R-prime pru + plasmid pJF4 and the demonstration that pJF4 could 'switch off' alginate biosynthesis in PAO strains containing muc-2 or muc-22 and muc mutations in four of five clinical MPA isolates tested [13] . Failure of pJF4 to complement muc-23 and a phenotypically similar mutation in the CF isolate P. aeruginosa 492a (muc-492a) confirmed previous linkage data which suggested that these muc mutations represented a second muc locus between hisl and proB [12, 13] .
By the mid 1980s, the application of molecular studies had led to a rapid expansion in knowledge of alginate regulation including the location of other alginate gene clusters. Structural genes involved in the alginate biosynthetic pathway, represented by algD, encoding the key alginate biosynthetic enzyme, GDP mannose dehydrogenase, were located at the 34-min region [15] . Transcription of algD was shown to be dependent on algR, a regulatory locus mapping at the 9-rain region [16] . Subsequently, a link between algR, algD and muc mutations was confirmed by evidence that muc mutations modified transcription of algD either positively or negatively when stimulated by raised osmolarity or nitrogen limitation and that the modification was dependent upon individual muc alleles [17] . The key role of muc mutations in the environmental regulation of mucoidy explains previous observations which indicated that, although increased osmolarity was associated with increased alginate production in some MPA, this stimulus alone was not sufficient to induce mucoidy in NMPA. Further studies indicated that muc mutations also influence other pseudomonas virulence determinants. Use of PAO568 (muc-2) [10, 12] which displays increased algD transcription and mucoidy in increasing concentrations of NaC1 [17] , indicated that muc-2 is involved in a see-saw expression pattern of algD and the elastase stuctural gene lasB suggesting that the lasB gene and the alginate system are co-ordinately regulated with muc-2 acting as a global regulator [18] .
Physiological changes in response to environmental stimuli such as osmolarity and anaerobicity can be regulated at transcriptional level by alterations in DNA superhelicity in Escherichia coli and Salmonella typhimurium [19] . Similarly, there is circumstantial evidence that alginate biosynthesis may be regulated by DNA supercoiling or protein-DNA binding controlled by a gene product of the muc region. Firstly, the use of an algD.xylE reporter system [17] indicated that the gyrase inhibitor, ciprofloxacin, caused algD to be switched off at concentrations as low as 5% of the minimum inhibitory concentration (Fig. 1) . Secondly, individual muc mutations are associated with different susceptibility to gyrase inhibitors but not other classes of antibiotics (Table  1 ). In addition, transcription of algD depends on another unusual genetic element, algP, which aeruginosa in the presence of ciprofloxacin. Measured by transcriptional fusion assay with an algD-xylE fusion [17] .
The MIC of ciprofloxacin is 1.5 mg/l and the mucoid phenotype is associated with levels of reporter gene activity > 5 units.
encodes a product whose carboxy-terminal domain is similar to carboxy-terminal tails of histone Hl-like DNA binding proteins which are emerging as another class of common regulators of virulence in pathogenic bacteria [20] . The earlier observation that R-prime plasmids containing wild-type muc genes were capable of complementing muc mutations in trans to produce a non-mucoid phenotype suggested that the product of mac genes may be a cytoplasmic regulator. Alternatively, since muc affects algR, a transcriptional regulator of alginate biosynthetic genes, muc could participate in the sensory processes being locked in the 'on' position leading to constitutive expression of alginate and the mucoid phenotype [17] . Table 1 MICs for isogenic derivatives of P. aeruginosa PAO 
Muc mutations in the CF lung
Early studies have shown that MPA isolated in vitro from CF patients are heterogeneous in their ability to produce the mucoid phenotype on different agar media [21] . Examination of 50 independent MPA showed that most isolates responded to environmental stimuli and that in the majority raised osmolarity down-regulated algihate biosynthesis as observed with muc-23 [17] . An ongoing study, focussing on the MPA population in CF sputum at the transition from the nonmucoid to the mucoid phenotype indicates that in all seven patients studied to date the MPA population is heterogeneous in its environmental response (authors' unpublished results). Heterogeneity at this early stage of colonisation suggests that the CF lung provides a variety of environmental niches in which appropriately responsive individu~l muc mutations emerge from the original non-mucoid colonisers rather than the emergence of a single mutation which undergoes subsequent adaptation.
The evidence that a variety of muc mutations affect regulation of alginate biosynthesis in response to environmental stimuli both in vitro and in vivo presents a clear indication of the complexity of the alginate regulatory system and the hazards of using studies of individual MPA to generalise on the nature of the mucoid phenotype. For example, the extensive use of P. aeruginosa 8821 and its derivatives [22] has contributed significantly to knowledge of the molecular biology and enzymology of alginate biosynthesis. Strain 8821 exhibits enhanced mucoidy in the presence of raised osmolarity and supported the attractive hypothesis that elevated salt concentrations in CF lungs may favour alginate biosynthesis. This type of environmental response, however, is shown by a minority of CF isolates; a more common response is an absence of any significant response to this factor or loss of mucoidy when MPA are grown on media with high osmolarity [17] . Similarly, in an elegant review of their gene replacement studies [23] , Ohman and Goldberg de- Table 2 Genes and gene products involved in control of mucoidy in Pseudomonas aeruginosa 
Genetics of mucoidy
After a relatively long hiatus following the initial mapping of muc mutations, the genetics of mucoidy in P. aeruginosa has recently received significant attention. As a result of the work of several groups [20, 22, 23] , many previously unsuspected details of the regulation of alginate production have been unravelled. Table 2 illustrates how control of mucoidy includes bacterial signal transduction systems (such as AlgR and AlgB), elements controlling nucleoid structure Hpl, alternative name AlgP [24] , and, possibly, factors affecting superhelicity (see Fig. 1 and Table 1 ). Interestingly, similar types of regulatory systems control virulence determinants in many other bacterial pathogens. Thus, the control of mucoidy in Pseudomonas has become one of the focal systems for analysis of how bacterial pathogens adapt to the host environment. Two extensively studied check points in the control of mucoidy are: (i) transcriptional activation of algD [15] , the gene encoding GDPmannose dehydrogenase (GMDH) [15] ; and (ii) its regulation by algR. Transcriptional activation of algD is a sine qua non for the mucoid phenotype.
GMDH catalyses double oxidation of GDPmannose into alginate precursors, and channels sugar intermediates into the production of the exopolysaccharide. Activation of algD is absolutely dependent on AlgR. AlgR binds to the algD promoter in an unusual fashion, to sites compris-327 ing a lopsided palindrome with symmetrical sequences separated by over 340 nucleotides [25, 26, 36] . This arrangememt probably reflects the need for proper orientation of proteins bound to DNA with regard to their interaction with RNA polymerase and potential AIgR-AlgR interactions. Because of the high affinity binding sites located far upstream from the algD mRNA start site, activation of algD most likely involves DNA looping or bending. Participation of such a process may render algD promoter sensitive to local nucleoid structure ( [17, 25] Fig. 1 ). The AIgR protein belongs to the superfamily of bacterial signal transduction systems [27] . AlgR homologues, termed response regulators, are known to undergo a phosphorylation-dependent modulation of their activity [28] . This process relies in many instances on a second protein, commonly a histidine kinase, which, in response to environmental signals, undergoes ATP-dependent autophosphorylation followed by a phosphotransfer reaction to response regulators such as AIgR. This type of regulatory signalling is the preponderant mode of how bacteria control their central metabolic functions and complex phenotypes such as expression of virulence factors. A typical second component interacting with AIgR has not been identified. It has been proposed that algQ [16] encodes the second component, but when this gene was sequenced [29, 30] its predicted gene product did not show similarity to any known histidine protein kinase. A recent study with crude protein extracts and partially enriched proteins led to a proposal that AlgO may act as a novel GTP-dependent kinase that phosphorylates a polypeptide of a similar electrophoretic mobility as AIgR [31] . However, the use of appropriate controls such as algR mutants and monoclonal antibodies against AIgR demonstrated that this polypeptide was not AlgR [32] . Furthermore, it has been recently demonstrated [32] that AlgR can be phosphorylated by typical histidine protein kinases using heterologous kinases such as CheA, normally involved in chemotoaxis, and BvgS, a central regulator of virulence in Bordetella pertussis. Thus a kinase (sensor) typical of two component signal transduction systems, may exist in the alginate system. By analogy with other systems, phosphorylation is expected to activate AlgR. If this is true, an exciting possibility, originally proposed by Deretic et al. [20] , is to develop inhibitors specific for bacterial signal transduction. It is expected that development of such potential drugs may provide a new line of antimicrobial agents for use in the treatment of MPA infections in CF patients.
Interestingly, small molecular mass phosphodonors such as acetyl phosphate and carbamoyl phosphate (participants in intermediary metabolism), have been recently shown to interact with AlgR, possibly phosphorylating it or interfering with the phosphorylation process [32] . Similar reactions have been reported for several other response regulators such as CheY, another protein controlling chemotaxis [33] , and PhoB, the central regulator of phosphate metabolism [34] . Carbamoyl phosphate is an important intermediate in pyrimidine and arginine synthesis. In P. aeruginosa, which is generally considered to be a non-fermenter, it can be used for substrate level ATP synthesis from arginine under anaerobic conditions [35] . Acetyl phosphate is related to the synthesis of acetyl-CoA, a key substrate for the TCA cycle, and is an important intermediate in utilization of pyruvate, glucose and acetate as well as in ATP synthesis [35] .
Exciting new questions emerge: Do these intermediates affect regulation of mucoidy? Are intracellular levels of these compounds related to environmental conditions that affect mucoidy? Are these molecules a new 'currency' for phosphate exchange and phosphorylation? Can direct participation of small molecular mass phosphodonors help explain the perplexingly large number of environmental factors which affect mucoidy? Are muc mutations or the function of muc genes related to or affected by levels of these compounds?
More than ever before, it is becoming critical to understand the nature of genetic elements such as muc which are responsible for or participate in conversion to mucoidy. The existence of mapped mutations [10, 12, 14] is playing an invaluable role in facilitating their cloning and molecular characterisation. In collaboration with Dr.
Bruce Holloway, several genes that affect mucoidy which map in the region known to contain muc mutations are currently being analysed. An analysis of one of the loci, mapping near muc-2 or identical to it, indicates the presence of two genes (algU and algV). The algU gene encodes a polypeptide of 27 kDa (P27). A downstream gene encodes a polypeptide of 20 kDa (P20). The algU gene has been sequenced, and the primary structure of its predicted gene product indicates that this could be an alternative sigma factor (D.W. Martin, B.W. Holloway and V. Deretic, in preparation). Its homologue is a sigma factor participating in the early stages of sporulation in Bacillus subtilis. This suggests that mucoidy may represent a developmental process. Sporulation in B. subtilis also involves signal transduction systems, such as AlgR homologues SpoOA and SpoOF [27] , and there may be several more parallels between the two systems. It is of interest that alginate plays a role in another developmental process, viz. in encystment of Azotobater vinelandii [12] .
CONCLUDING REMARKS
In conclusion, the current cloning and molecular analysis of muc mutations may help uncover what is now considered to be a holy grail sought by many scientists in CF microbiology. Once reasons and mechanisms for the emergence of the mucoid phenotype of P. aeruginosa in CF patients are clarified and the nature of muc genes and mutations unveiled, it may be possible to intervene with the processes conducive to mucoidy and prevent establishment of chronic P. aeruginosa infections in CF lungs.
